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Cholesterol crystal embolization (CCE) is a dreaded
complication of radiology, vascular surgery, and/or
anticoagulation in patients with atherosclerosis and
ulcerated aortic plaques. It also represents a cause of early
graft failure and of poor results of renal artery surgery.
Crystals lodge in small caliber renal arteries, where they
induce early, transitory thrombosis followed by delayed,
definitive obstruction by endarteritis, accompanied by
evidence of inflammation and eosinophilia. Massive CCE
leads to early oligoanuria. In subacute forms, renal
insufficiency is often delayed by weeks or months following
the triggering event. A third, chronic subset of CCE is easily
mistaken for atherosclerotic renal ischemia and/or
nephrosclerosis. The kidney is rarely the sole organ involved
in acute/subacute forms, in which the central nervous
system, the coronary arteries, the spinal cord, and the
mesenteric and pancreatic blood supply compromise
represent the main causes of death. Cutaneous, retinal, and
muscle involvement allow diagnosis by inspection or scarcely
invasive biopsies in about 80% of cases, whereas renal biopsy
as the only diagnostic procedure is required in 20% of cases.
Prevention is based on avoidance of endovascular radiology
maneuvers, vascular surgery, and excess anticoagulation in
atherosclerotic patients. Treatment of acute/subacute forms
of renal insufficiency consisting of stopping anticoagulation
and forbidding any new radiologic and/or vascular surgery
procedure; treating hypertension with angiotensin 2
antagonists and vasodilators, strict volemic control by loop
diuretics and ultrafiltration, along with parenteral nutrition
and prednisone, has been credited with improved outcome.
Iloprost may obtain favorable results. Statins definitely
ameliorate the renal and patient’s prognosis.
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Considering the progress of invasive endovascular proce-
dures, one can assume that the frequency of cholesterol
crystal embolism (CCE) increases with passing time. In fact,
although atheroembolism ranks among the dreaded compli-
cations of radiology and of vascular surgery, it is still
underdiagnosed and its treatment is not clearly codified.
CCE should no longer be the ‘Cinderella of nephrology’.1
However, few papers deal with numbers of patients allowing
statistical analysis on this common complication of athero-
sclerotic ischemic renal disease,2 a masquerader which
manifests with such disparate signs and symptoms that the
diagnosis is far from being readily made. An extensive review
by Scolari et al.3 thoroughly analyzed the spectrum of CCE
that spans the fortuitous discovery of a few crystals at autopsy
to the life-threatening occurrence of multiorgan involvement
including acute renal failure.
EPIDEMIOLOGY AND FREQUENCY
CCE is mostly a complication of widespread atherosclerosis
in the white Caucasian. It is apparently rare in Blacks,4 or
underdiagnosed owing to the difficulty to assess livedo and
purple discoloration on black skin. The frequency of CCE is
variably appreciated, depending on systematic search on
autopsy material as opposed to clinical diagnosis. Fine et al.5
reviewed 221 histologically proven cases. Among 75 cases,
clinical diagnosis of gastrointestinal and pancreatic involve-
ment was made in 26.7%, of renal involvement in 22.7%, and
of spleen, liver, and adrenal involvement in 1.33%. At
autopsy, among 92 cases, the respective figures were 95.6,
83.7, and 100%. The frequency of localizations to viscera is
roughly proportional to their blood flow. Considering that
the renal blood flow represents 1/5th to 1/4th of the cardiac
output, it comes as no surprise that CCE ranks among
common etiologies of acute, subacute, and chronic renal
disease in atherosclerosis.
BACKGROUND
The typical candidate for CCE is a male (male/female ratio
91/9% in Belenfant et al.6), in his 60s, smoker, lean, and
suffering from various manifestations of atherosclerosis.3,7
When sought by angiography or magnetic resonance imaging
virtually all patients (97% in Belenfant et al.6) have plaques
on their thoracic aorta. Strong correlations appear between
CCE and certain localizations of the atherosclerotic process.
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Belenfant et al.6 found that 67% of their patients had an
aortic abdominal aneurysm. Renal artery imaging following
coronarography identifies the frequency of renal artery
stenoses in patients with coronary disease, a frequency of
B30% when their renal function is diminished.2 CCE is
common in renal artery atherosclerotic disease. In 1988, we
found that in 32 patients with atherosclerotic disease, 10 had
evidence of CCE to the kidneys, including six in whom the
diagnosis was made by histology.8 The Cleveland Clinic
Foundation Urology and Pathology team9 evaluated the
impact of CCE on morbidity and survival after surgical
revascularization for atherosclerotic disease. CCE was found
in the intraoperative biopsy specimen in 16/44 (36%) of the
patients. The survival and the incidence of morbid events
were significantly different at 6 years in patients with, as
opposed to those without CCE. Interestingly, there were no
distinguishing preoperative clinical or laboratory features in
patients with and without atheroembolic renal disease.
TRIGGERING EVENTS
CCE is iatrogenic in a majority of cases: 79% in Scolari et al. 3
and 76% in Belenfant et al.6 experience. The most common
triggering events7 consist of angioplasty or vascular surgery
(50 and 15%, respectively in Scolari et al.,3) and long-term
anticoagulant therapy (76% in Belenfant et al.6). Fibrinolytic
therapy is another reported etiology.3,10,11 The atherosclerotic
patient may also suffer spontaneous detachment of a plaque,
or low grade, clinically silent migration of crystals from the
aortic wall. Cross12 in a series of 372 necropsies estimated the
incidence of ‘spontaneous’ cholesterol embolism to be 1.9%.
RENAL INVOLVEMENT
Renal complications of CCE cover three scenarios: acute,
subacute, and chronic renal failure. Acute renal failure (ARF)
occurring within B7 days following the inciting event is
observed in about one-third of the cases. It is often
fulminant, following massive migration of crystals, and the
kidney is seldom if ever the sole organ involved. This
multiorgan involvement differentiates CCE from early ARF
from iodinated contrast media toxicity,7 or that complicating
vascular surgery. Depending on the site of plaques, multiple
vital organ damage has been described, including in a
descending progression from the aortic arch to the
abdominal aorta, the retina, the central nervous system, the
coronary arteries, the spinal cord artery, the pancreas, the
mesenteric blood supply, and the adrenal glands. A case of
CCE to the lung with alveolar hemorrhage adds this
condition to the list of pulmonary-renal syndromes.13
Oligoanuria appears rapidly and is accompanied with severe
hypertension or the abrupt aggravation of previous hyper-
tension. Half of 129 patients reported by Lye et al.14 were
hypertensive, most of them severely. Flank pain and/or
hematuria are uncommon. Conversely, abdominal pain and
discomfort is frequent, due to mesenteric and pancreatic
ischemia. Massive CCE usually involves lower limb muscles.
Gastrointestinal and muscle ischemia explain wasting.
Cutaneous involvement is virtually constant, consisting of
purple toes (Figure 1), lower limb livedo reticularis, which
may extend to the lumbar area. Painful, localized, or
complete necrosis of toes may require amputation.
The subacute subset is particular, and deceptive in that
renal manifestations appear weeks or months after the
inciting event. Frock et al.15 in 17 patients with CCE
observed that ARF occurred 5.370.9 weeks after angio-
graphy. Renal function impairment often develops in
a stepwise fashion over the following weeks. Each aggrava-
tion follows a triggering event eliciting another shower of
crystals, such as repeat angiography, vascular surgery, and/or
anticoagulation.6
In most cases of CCE proteinuria is nonsignificant. Some
cases however may be accompanied by nephrotic proteinuria.
Greenberg et al.16 found 10 cases of focal segmental
glomerulosclerosis in 24 patients with CCE, whose protein-
uria reached nephrotic levels. Nevertheless, the relationship
between CCE, focal segmental glomerulosclerosis, and
nephrotic proteinuria is not perfectly established. Other
glomerular lesions, such as diabetic glomerulopathy, cannot
be excluded. Also, high-renin malignant hypertension
may also induce significant proteinuria. In the same line,
atherosclerotic renal artery stenosis, which is a common
finding in patients with CCE, may be accompanied by focal
segmental glomerulosclerosis and abundant proteinuria,
without documented evidence of concomitant CCE.17–19
These observations have fostered speculations on the
relationship between renal ischemia and focal segmental
glomerulosclerosis, including its collapsing variant.20
The chronic subset is frequent and underdiagnosed,
understandably if one considers the patients’ background.
It manifests by a slowly progressive form of renal insuffi-
ciency with bouts of aggravation. In an atherosclerotic
patient in his 60s, suffering from hypertension and renal
insufficiency, and in whom stenotic renal artery plaques are
common, low-grade CCE to the kidneys is usually ascribed to
nephrosclerosis.21
PATHOPHYSIOLOGY
Figure 2 shows the source of atheroembolism. Cholesterol
crystals are too small to close up the artery in which they
Figure 1 | Typical appearance of cutaneous lesions. This figure
shows a purple toe (-) and an area of livedo reticularis (m).
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lodge, but induce an endothelial inflammatory reaction,
which leads to complete obstruction within weeks or months.
Crystals are seen in the lumen of arteries, where they appear
as elongated, biconvex transparent clefts, dissolved by the
tissue processing. Some small crystals may enter a glomerular
afferent arteriole. Early ARF may follow massive crystal
into the renal arterial tree. However, the onset of renal
insufficiency is often delayed for weeks or months. This
silent spell is explained by the endothelial reaction to crystals
followed by obstruction. From this viewpoint, CCE induces
a form of anti-neutrophil cytoplasmic antibody negative
angiitis, accompanied by clinical and laboratory features of
inflammation: rapid erythrocyte sedimentation rate high
C reactive protein levels, high eosinophil blood counts, and
much more rarely hypocomplementemia.3,6,7,22 The patho-
physiology of these last two findings is currently unclear.
Animal experiments have been based on the injection of
cholesterol crystals into the renal artery followed by serial
observations of the vascular lesions.23 Shortly after lodging in
the lumens crystals induce platelet aggregation and throm-
bosis. Thereafter the thrombus undergoes lysis. Subsequently,
from 5 days to 1 month onwards, progressive fibrous
endarteritis leads to complete arterial obstruction (Figure 3).
The fate of cholesterol crystals is to persist indefinitely. These
findings help understand the course of the human disease:
massive CCE complicated with early ARF induces widespread
thrombosis of the renal arterial tree with scattered multi-
focal infarction, whereas milder forms progress to delayed,
obstructive inflammatory reaction to foreign bodies.
DIAGNOSIS
The diagnosis is readily made when fulminant CCE occurs
within days after radiology maneuvers or vascular surgery,
and is accompanied by purple toes and livedo reticularis. It is
more difficult in the subacute subset, when renal insuffi-
ciency appears or worsens weeks later, especially when the
clinician’s mind is not prepared to consider the likeliness of
atheroembolism. Yet, the diagnosis workup is rewarding
when lower limbs are examined and funduscopy carried out,
as cutaneous changes are almost constant and retinal crystals
are found in up to 25% of cases.3,6 The yield of nonrenal
biopsies is high. Lower limb skin biopsies, calf or thigh
muscle biopsies, bone marrow biopsies, and biopsies of the
gastric and the colon mucosa altogether disclose crystals in
about 80% of cases. It follows that renal biopsy may be
avoided in a majority of patients. When the diagnostic
workup is properly conducted, renal biopsy as the only
means of making a diagnosis of CCE is necessary in about
20% of cases only. However, histology is useful for diagnosing
CCE in the chronic, smoldering form of atheroembolism.
Zucchelli and Zuccala21 examined the kidneys of 136 patients
diagnosed as ‘hypertensive nephrosclerosis’. In total, 29.4%
had in fact biopsy evidence of cholesterol embolization, with
or without atherosclerotic renal artery stenoses, found in
26.5%. This illustrates the interest of renal histology in case
of rise in serum creatinine levels unexplained by a recent
factor, such as a change in antihypertensive therapy, a
nephrotoxic or immunizing medication, and iodinated
contrast media injection. The discovery of crystals is a strong
incentive to forbid any form of anticoagulant treatment
and to limit the indications of renal artery revascularization
to cases where rescue from impending renal loss appears
mandatory.6
DIFFERENTIAL DIAGNOSIS
Among many diagnostic challenges, renal artery athero-
sclerotic stenosis and hypertensive nephrosclerosis stand out
as common deceptive conditions. Iodinated contrast media
toxicity is another cause of confusion with the early, acute
form of CCE induced renal insufficiency, especially in
patients at risk, mostly diabetics with renal insufficiency. In
the others, the time course of renal insufficiency is different
from that of iodinated contrast media toxicity where the rise
in serum creatinine appears early, plateaus between 5 and 10
days and is followed by a slow return to baseline.7 Rapidly
progressive glomerulonephritis is easily ruled out as the
urinary findings in CCE are not nephritic. In subacute forms,
skin involvement, fever, wasting, laboratory evidence of
inflammation, and high eosinophil counts have often been
Figure 2 | Ulcerated aortic plaque. A clot (*) separates cholesterol
crystals (t) from the bloodstream. Clot dislodgement or lysis sets
crystals free. Once showered into the bloodstream, they lodge in
renal arteries with a diameter of 150–200 mm, mostly arcuate and
interlobular arteries. Courtesy: Patrick Bruneval MD.
Figure 3 | Renal biopsy at a late stage. Cholesterol crystals appear
as transparent clefts. This interlobular artery is obstructed by
endarteritis and fibrosis. Toluidine blue, original magnification:
 400.
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mistaken for vasculitis and published as ‘pseudo-polyangiitis’.
The availability of anti-neutrophil cytoplasmic antibodies
makes this confusion unlikely. At any rate, the polymorph
clinical and renal expression of CCE may justify renal
histology in case of hesitance.
CCE IN RENAL ALLOGRAFTS
To date, 25 cases of CCE in renal transplants have been
published,11 too scarce a number to reflect the real incidence
of this complication. The source of crystals can be ascribed
to the donor at the time of procurement (12/25 cases),
to recipient’s atherosclerosis (8/25 cases), to invasive radio-
logy (2 cases), or to anticoagulation/fibrinolytic treatment
(2 cases). The time course to the graft compromise (when
specified) is short (6–18 days) when emboli emanate from the
donor’s artery and apparently long, in the order of years
when the recipient is atherosclerotic. In fact, CCE may be
triggered up to 19 years after grafting by angioplasty,
anticoagulation, or fibrinolytic therapy.
CCE occurring at the time of transplantation led to rapid
graft loss in eight cases and recovery in five. In iatrogenic
CCT, all kidneys but one recovered renal function. CCE due
to the recipient’s atherosclerosis had a rather better prognosis
with recovery in 6/9 cases.
One may postulate that CCE is more common in renal
transplantation than thought, and often misinterpreted as
acute or chronic rejection, or resulting from calcineurin
inhibitor toxicity. Outside the case of rapid graft failure
followed by thorough pathologic examination of a surgically
removed transplant, many cases fail to be diagnosed on the
limited amount of tissue yielded by a thin needle renal biopsy.
TREATMENT
There is no curative treatment of CCE. Therapeutic
modalities are symptomatic and preventive.
Until recently prognosis was considered disastrous. At the
time of Fine et al.’s publication,5 a majority of cases dealt with
autopsy series. In fact, as in other forms of ARF, death from
CCE is not the consequence of renal failure but of
concomitant visceral ischemia. Patients with severe brain,
coronary, spinal cord, mesenteric, and/or pancreatic necrosis
are doomed to die, irrespective of the degree of renal failure.
Belenfant et al.6 elaborated a treatment protocol based on:
(i) stopping any form of anticoagulation and forbidding any
new radiologic and/or vascular surgery procedure; (ii)
treating hypertension drastically with angiotensin 2 antago-
nists and vasodilators, along with strict volemic control by
loop diuretics and dialysis/ultrafiltration; (iii) implementing
parenteral nutrition; and (iv) giving  13 mg=kg=day of
prednisone to improve appetite and relieve abdominal
discomfort. Peritoneal dialysis was deemed inappropriate,
owing to gastrointestinal ischemia, risk of peritonitis and
the loss of serum albumin pertaining to peritoneal dialysis.
In-hospital mortality was 16%. Survival at 1 year was 87%
and at 4 years 52%, which compared favorably with
corresponding figures published earlier. However, some form
of bias might have influenced these figures as Scolari et al.,3
using a conservative regimen obtained roughly similar
results.
Elinav et al.24 treated four patients suffering from CCE
complicated with painful cutaneous necrotic lesions and
renal insufficiency with the prostacyclin analog, iloprost. The
drug was administered continuously in gradually increasing
dosage for 10–14 days followed by 8 h infusions thrice a week
for 3 weeks and thereafter once a week. At 1 month, this
regimen had clearly improved skin lesions, pain, and renal
function. To the best of my knowledge, this is the only
publication on the favorable effect of iloprost in CCE, a result
that would deserve further clinical trials.
Prevention is based on weighing the pros and cons of
anticoagulation, invasive radiology, and vascular surgery in
patients with atherosclerosis. The medical, radiological, and
surgical team must join their experience to make a decision
between the hazards of treatment and the risk of CCE.
Statins, which stabilize, and even obtain regression of
atherosclerotic plaques,25 offer hope that the incidence of
CCE might diminish: a prospective study showed that they
ameliorate the renal and patient outcome in CCE.26
ACKNOWLEDGMENTS
Figures 1 and 2 were reprinted from EMC Ne´phrologie, 18-046-A-10,
Meyrier A. Athe´roscle´rose et reins, 2003, with permission from
Elsevier SAS, Paris, France
REFERENCES
1. Scoble JE, O’donnell PJ. Renal atheroembolic disease: the Cinderella of
nephrology. Nephrol Dial Transplant 1996; 11: 1516–1517.
2. Meyrier A, Hill GS, Simon P. Ischemic renal diseases: new insights in old
entities. Kidney Int 1998; 54: 2–13.
3. Scolari F, Tardanico R, Zani R et al. Cholesterol crystal embolism: a
recognizable cause of renal disease. Am J Kidney Dis 2000; 36: 1089–1109.
4. Saklayen MG. Atheroembolic renal disease. Preferential occurrence in
whites only. Am J Nephrol 1989; 9: 87–88.
5. Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review
of 221 cases in the English literature. Angiology 1987; 42: 769–784.
6. Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves
survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis
1999; 33: 840–850.
7. Thadhani R, Camargo C, Xavier R et al. Atheroembolic renal failure after
invasive procedures. Natural history based on 52 biopsy-proven cases.
Medicine 1995; 74: 350–358.
8. Meyrier A, Buchet P, Simon P et al. Atheromatous renal disease. Am J Med
1988; 85: 139–146.
9. Krishnamurthi V, Novick AC, Myles JL. Atheroembolic renal disease: effect
on morbidity and survival after revascularization for atherosclerotic renal
artery stenosis. J Urol 1999; 161: 1093–1096.
10. Glassock RJ, Ritz E, Bommer J et al. Acute renal failure, hypertension and
skin necrosis in a patient with streptokinase therapy. Am J Nephrol 1984;
4: 193–200.
11. Scolari F, Tardanico R, Pola A et al. Cholesterol crystal embolic disease in
renal allografts. J Nephrol 2003; 16: 139–143.
12. Cross SS. How common is cholesterol embolism? J Clin Pathol 1991; 44:
859–861.
13. Sabatine MS, Oelberg DA, Mark EJ, Kanarek D. Pulmonary cholesterol
crystal embolization. Chest 1997; 112: 1687–1692.
14. Lye WC, Cheah JS, Sinniah R. Renal cholesterol embolic disease. Am J
Nephrol 1993; 13: 489–493.
15. Frock J, Bierman M, Hammeke M, Reyes A. Atheroembolic renal disease:
experience with 22 patients. Nebr Med J 1994; 79: 317–321.
16. Greenberg A, Bastacky SI, Iqbal A et al. Focal segmental
glomerulosclerosis associated with nephrotic syndrome in
cholesterol atheroembolism. Am J Kidney Dis 1987; 29: 334–344.
Kidney International (2006) 69, 1308–1312 1311
A Meyrier: Cholesterol crystal embolism m i n i r e v i e w
17. Gephardt GN, Tubbs R, Novick AC et al. Renal artery stenosis,
nephrotic-range proteinuria, and focal and segmental glomerulosclerosis.
Cleveland Clin Q 1984; 51: 371–376.
18. Thadhani R, Pascual M, Nickeleit V et al. Preliminary description of focal
segmental glomerulosclerosis in patients with renovascular disease.
Lancet 1996; 347: 231–233.
19. Conlon PJ, O’riordan E, Kalra PA. New insights into the epidemiologic and
clinical manifestations of atherosclerotic renovascular disease. Am J
Kidney Dis 2000; 35: 573–587.
20. Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis.
Nat Clin Pract Nephrol 2005; 1: 44–54.
21. Zucchelli P, Zuccala A. The diagnostic dilemma of hypertensive
nephrosclerosis: the nephrologist’s view. Am J Kidney Dis 1993; 21:
87–91.
22. Kasinath BS, Corwin HL, Bidani AK et al. Eosinophilia in the diagnosis of
atheroembolic renal disease. Am J Nephrol 1987; 7: 173–177.
23. Warren BA, Vanes O. The ultrastructure of the stages of
atheroembolic occlusion of renal arteries. Br J Exp Pathol 1973;
54: 469–478.
24. Elinav E, Chajek-Shaul T, Stern M. Improvement in cholesterol emboli
syndrome after iloprost therapy. BMJ 2002; 324: 268–269.
25. Corti R, Fuster V, Fayad ZA et al. Lipid lowering by simvastatin induces
regression of human atherosclerotic lesions: two years’ follow-up by high
resolution noninvasive magnetic resonance imaging. Circulation 2002;
106: 2884–2887.
26. Scolari F, Ravani P, Pola P et al. Predictors of renal and patient outcomes
in atheroembolic renal disease: a prospective study. J Am Soc Nephrol
2003; 14: 1584–1590.
1312 Kidney International (2006) 69, 1308–1312
m i n i r e v i e w A Meyrier: Cholesterol crystal embolism
